VIETNAMESE GERMAN SCIENTIFIC SYMPOSIUM HUE 2017

v.l. Dr. Minh (Hue), Prof. Cao Ngoc Thanh (Rektor der Medizinischen Universität Hue), Prof. Tran Huu Dang (Hue), Prof. Volker Klauss (München), Prof. Hans-F. Vöhringer (Berlin), PD Dr. Wolfsgang Fehske (Köln), Prof. Florian Krötz (Starnberg), Prof. Si Huyen Nguyen (HCMC/Helmstedt), Dr. Stefan Winter (Köln), Dr. Dinh Quang Nguyen (Köln), Dr. Tran Thong (USA), Dr. Birke Schneider (Lübeck), Sarah Klauss (München) Dr. Irmtraut Kruck (Ludwigsburg), Dr. Mareike Juliana Brunold (Köln), Prof. Huynh Van Minh (Hue)

VIETNAMESE GERMAN SCIENTIFIC SYMPOSIUM HUE 2017

20 Years Anniversary of the German Vietnamese Association of Cardiology (DVFK)
01.12.2017
 
Venue: Hue University of Medicine and Pharmacy
Time: 8:00 – 13:00

Organization:
 
. Hue University of Medicine and Pharmacy
. Vietnamese Heart Association Thua Thien Hue
. German Vietnamese Association of Cardiology/ Deutsch-Vietnamesischer Förderkreis für 
  Kardiologie e.V. (DVFK)
. Vietnamese German Academy for Science and Education in Cardiology and
  Cardiovascular Surgery (VGAC)
 
 
Lectures:
 
Echocardiography in oncological diseases
Dr. Irmtraut Kruck, Cardiology Clinic, Ludwigsburg, Germany

Echocardiography for early detection of cardio toxicity in cancer-patients chemotherapy induces impairment of LV- and RV structure, function and mechanics by different complex mechanism. For this comprehensive assessment of LV/RV structure function and mechanics is necessary in cancer patients before, during and after treatment.
Echocardiography is the best image modality because of its availability in every day clinical practice and allows early detection of reduced LV- and RV-function. Therefore it is necessary to perform an echocardiographic examination including all available technics (pulsed and tissue Doppler and 2-D-Strain) in echocardiographic laboratories which have the appropriate equipment and diagnostic expertise. Cardiac dysfunction caused by cardiotoxic treatment can appear at any time during or after therapy and sometimes even after years. Recommendations on the frequency of standardized follow-up examinations exist, but they vary between the specialist societies. Increased morbidity and mortality due to cardiotoxic treatment are now well known, but still too few patients undergo appropriate examinations. Early detection and treatment of existing heart failure and treatment should improve the clinical outcome of these patients.

Beyond coronary angiography: Why do we need additional invasive techniques?
Prof.Dr. Volker Klauss, Cardiology Munich City Centre, Munich, Germany
 
The decision for interventional treatment of a coronary lesion should be based on symptoms and prove of ischemia. However, in clinical practice, stenoses are often treated depending on the angiographic image, because symptoms are not clear and tests for ischemia have not been performed or the tests are inconclusive. By means of intracoronary pressure measurements (i.e. determination of fractional flow reserve – FFR,  or instantaneous wave-free ratio - iFR) the hemodynamic relevance of a coronary stenoses can be determined during coronary angiography especially in intermediate lesions and thus the decision to treat or not to treat is based on an objective test of ischemia.
Regarding coronary morphology angiography is the standard for imaging of the coronary tree. However, this technique has limitations. Intravascular ultrasound (IVUS) allows a cross-sectional view of the coronary arteries. IVUS may help to diagnose and assess stent underexpansion and malapposition and to guide interventions in complex cases.
Another recent modality based on infrared light is the optical coherence tomography (OCT)with a resolution better than IVUS. It is now used for evaluation of new stent technologies i.e. bioabsorbable scaffolds.

Transcatheter treatment of severe mitral regurgitation using the mitraclip system
Prof. Dr. Florian Krötz, Clinic Starnberg, Department of Cardiology, 82319 Starnberg, Germany

The interventional treatment of mitral valve regurgitation using the MitraClip procedure is a valuable tool for treatment of inoperable patients or patients at high operative risk. Its efficiency in reducing mitral regurgitation has been proven in the EVEREST II study, and use of the technique has rapidly grown worldwide and especially in Germany since then. In suitable patients the method is excellent for treating primary mitral valve regurgitation but has also great potential in patients with heart failure and secondary mitral valve regurgitation, which often show poor outcomes following surgery.
Current recommendations and clinical data concerning the method rely largely on data from the EVEREST II trial. Registries, like the German TRAMI register however, survey a large number of patients, so today there is a good insight into the prerequisites of building an interventional mitral valve program, the need for specialized screening of patients, and for a dedicated interventional setup during implantation. This and the essential procedural techniques will be outlined.
 
Catheter Ablation of Atrial Fibrillation in Patients with heart Failure: Evidence for prognostic indication?
Dr. Dinh Quang Nguyen, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 

Catheter Ablation of Atrial fibrillation is well established in symptomatic patients. But it is still a symptomatic indication.
In Patients with reduced LV ejection fraction and heart failure, the success rate of catheter ablation remains challenging and controversial.
This presentation gives an update in publications and highlights a new published randomized study (Castle-AF), which has shown a prognostic benefit of catheter ablation in Patients with heart failure.
 
Diagnostic value of cardiac MRI in patients with heart failure
Dr. Birke Schneider, Lübeck, Germany

Heart Failure (HF) is a clinical syndrome characterized by typical symptoms and clinical signs which are caused by a structural and/ or functional cardiac abnormality, resulting in reduced cardiac output and/ or elevated intracardiac pressures at rest or during stress.
Demonstration of an underlying cardiac cause is central to the diagnosis of HF. This is usually a myocardial abnormality causing systolic and/or diastolic ventricular dysfunction. However, abnormalities of the valves, pericardium, endocardium, heart rhythm and conduction can also cause HF, and more than one abnormality is often present. Identification of the underlying cardiac problem is crucial for therapeutic reasons, as the precise pathology determines the specific treatment used.
Cardiac imaging plays a central role in the diagnosis of HF and in guiding treatment. Of several imaging modalities available, echocardiography is the method of choice in patients with suspected HF, for reasons of accuracy, availability (including portability), safety and cost. However, the reliability of the echocardiographic study is highly dependent on the operator and centre experience and the image quality. Transthoracic echocardiography (TTE) nevertheless is regarded the primary method for assessment of systolic and diastolic function of both left and right ventricles and for the evaluation of valvular function.
Cardiac magnetic resonance imaging (CMRI) is nowadays acknowledged as the gold standard for the measurements of volumes, mass and ejection fraction of both the left and right ventricles (Class I Level C in the ESC Guidelines on HF 2016). It is the best alternative cardiac imaging modality for patients with nondiagnostic echocardiographic studies (particularly for imaging of the right heart) and is the method of choice in patients with complex congenital heart diseases.
In addition, CMRI also allows tissue characterization and thereby can be useful for establishing HF aetiology. CMRI is the preferred imaging method to assess myocardial fibrosis using late gadolinium enhancement (LGE) along with T1 mapping. CMRI with LGE allows differentiation between ischaemic and non-ischaemic origins of HF and myocardial fibrosis/ scars can be visualized. Different hyperenhancement patterns result from the pathophysiology of the underlying disease and help to establish the correct diagnosis. CMRI may also be used for the assessment of myocardial ischaemia and viability in patients with HF and coronary artery disease.
Various patients are presented where CMRI was essential in finding the cause of HF and had implications for patient management. Clinical limitations of CMRI will also be discussed.
 
Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents
Prof. Dr. Hans-F. Voehringer, DRK Clinics Berlin, Germany

Surgeons, cardiologists, primary care physicians, and anesthesiologists frequently have to determine the antiplatelet management in patients with coronary heart disease undergoing elective surgery. In Germany, more than 300 000 patients receive coronary stents annually, with up to 20% of these individuals requiring non-cardiac surgery within 2 years. There is definitive evidence that patients who have undergone percutaneous coronary interventions with stent implantation are at increased risk of perioperative major cardiac events (MACE) and that the risk is moderated by stent type (bare metal stent [BMS] vs. drug eluting stent [DES]), operative urgency, early discontinuation of antiplatelet therapy, and time from coronary intervention.
Guidelines recommend delaying non-cardiac surgery in patients after coronary stent procedure for 1 year after DES and for 6 weeks after BMS. The evidence underlying these recommendations is limited and conflicting. In a systematic review the perioperative antiplatelet management will be assessed to help clinicians with this common clinical case.
 
3D Echocardiography, from research to routine application: Today an obligatory application for a comprehensive investigation of the heart
PD Dr. Wolfgang Fehske, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 

A comprehensive investigation of systolic and diastolic heart failure patients by echocardiography
PD Dr. Wolfgang Fehske, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
 
Left atrial function, what can we derive from echocardiographic examinations with special respect to prognosis of stability after electrophysiological ablation for atrial  fibrillation
Mareike Juliana Brunold, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
 
Real world experience with resynchronization therapy: A detailed overview of more than 400 consecutive patients treated according to the guidelines
Stefan Winter, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
 
Sudden cardiac death beyond the existing guidelines: Does the Life Vest concept opens better solutions for our patients?  
Stefan Winter, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
 
FACULTY:
Dr. Mareike Juliana Brunold, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
PD Dr. Wolfgang Fehske, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
Prof. Dr. Volker Klauss, Cardiology Munich City Centre, Munich, Germany
Prof. Dr. Florian Krötz, Clinic Starnberg, Department of Cardiology, 82319 Starnberg, Germany
Dr. Irmtraut Kruck, Cardiology Clinic Ludwigsburg, Germany
Dr. Dinh Quang Nguyen, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
Prof. Dr. Si Huyen Nguyen, Vietnamese German Faculty of Medicine at Pham Ngoc Thach University HCMC,  HELIOS St. Marienberg Hospital Helmstedt, Germany
Dr. Birke Schneider, MD, Lübeck, Germany
Prof. Dr. Hans-F. Voehringer, DRK Clinics Berlin, Germany
Dr. Stefan Winter, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 

Ehrenplakette für Prof. Si Huyen Nguyen (HCMC/Helmstedt) und Prof. Volker Klauss (München), überreicht vom Herrn Nguyen Van Phuong, stellvertretenden Gouverneur von Thua Thien-Hue

Prof. F. Krötz (Starnberg)

---

Prof. V. Klauss (München) bei der HKU mit dem Ärzteteam der Universität Hue 

Gruppenbild mit Prof. V. Klauss. An der rechten Seite von Prof. Klauss ist Prof. H.A. Tien, Leiter des HKLs der Universitätsklinik Hue.